File downloaded on 2026-11-05
Source URL: https://medicines.health.europa.eu/veterinary/en/600000005949

Butagran Equi 200 mg/g Oral powder

Authorised

- Phenylbutazone

Product identification

Medicine name:
Butagran Equi 200 mg/g Oral powder

Active substance:
Phenylbutazone

Target species:
Horse

Route of administration:
Oral use

Product details

Active substance and strength:
Phenylbutazone
200.00 milligram(s) / 1.00 gram(s)

Pharmaceutical form:
Oral powder

Withdrawal period by route of administration:

Oral use:

- **Horse**
  - Meat and offal. no withdrawal period

Not for use in horses intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QM01AA01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Denmark

Available in:
Denmark

Package description:
Butagran Equi 200 mg/g 100 sachet (PET/LDPE/ALU/LDPE) 5 g or. pwdr.
Butagran Equi 200 mg/g 20 sachet (PET/LDPE/ALU/LDPE) 5 g or. pwdr.
Butagran Equi 200 mg/g 100 sachet ((ALU/LDPE/paper/LDPE)) 5 g or. pwdr.)
Butagran Equi 200 mg/g 20 sachets (ALU/LDPE/paper/LDPE) of 5g or. pwdr.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 18 of Regulation (EU) 2019/6)

Marketing authorisation holder:
Dopharma Research B.V.

Marketing authorisation date:
19/12/2012

Manufacturing sites for batch release:
Dopharma Research B.V.

Responsible authority:
Danish Medicines Agency

Authorisation number:
49966

Date of authorisation status change:
19/12/2012

Reference member state:
Belgium

Procedure number:
BE/V/0035/001

Concerned member states:
Austria Bulgaria Denmark Estonia Germany Italy Latvia Lithuania Poland Romania Spain United Kingdom (Northern Ireland)

Generic of:
600000064112

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 8/07/2026
Download

Labelling

Package Leaflet

Combined File of all Documents